Nanoparticles effectively target rapamycin delivery to sites of experimental aortic aneurysm in rats

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Shirasu, Takuro ^a   Koyama, Hiroyuki ^a,b,c   Miura, Yutaka ^a,d   Hoshina, Katsuyuki ^a   Kataoka, Kazunori ^a,d   Watanabe, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ELASTASE; MACROGOL; MATRIX METALLOPROTEINASE; NANOPARTICLE; RAPAMYCIN; AUTACOID; GELATINASE;

ABDOMINAL AORTA ANEURYSM; ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG STABILITY; DRUG TARGETING; ENZYME REPRESSION; INFLAMMATION; MACROPHAGE; MALE; MICROSCOPY; NONHUMAN; RAT; ANIMAL; AORTIC ANEURYSM; AORTIC ANEURYSM, ABDOMINAL; DISEASE MODEL; FLUORESCENCE MICROSCOPY; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; TISSUE DISTRIBUTION;

ANIMALS; AORTIC ANEURYSM; AORTIC ANEURYSM, ABDOMINAL; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GELATINASES; INFLAMMATION MEDIATORS; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; NANOPARTICLES; RATS; SIROLIMUS; TISSUE DISTRIBUTION;

EID: 84976621089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157813     Document Type: Article

References (53)

1. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: The Tromsø Study. Am J Epidemiol. 2001; 154(3):236-244. PMID: 11479188
2. Brewster DC, Cronenwett JL, Hallett JW Jr, Johnston KW, Krupski WC, Matsumura JS, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003; 37(5):1106-1117. PMID: 12756363
3. 2011 Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 124(18):2020-2045. doi: 10.1161/CIR.0b013e31822e80c3 PMID: 21959305
4. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002; 39(2):110-230. PMID: 11884965
5. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008; 117(14):1883-1889. doi: 10.1161/CIRCULATIONAHA.107.735274 PMID: 18391122
6. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996; 23 (2):336-346. PMID: 8637112
7. Shiraya S, Miyake T, Aoki M, Yoshikazu F, Ohgi S, Nishimura M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis. 2009; 202(1):34-40. doi: 10.1016/j.atherosclerosis.2008.03.020 PMID: 18482727
8. Golledge J, Cullen B, Moran C, Rush C. Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm. Cardiovasc Drugs Ther. 2010; 24(5-6):373-378. doi: 10.1007/s10557-010-6262-8 PMID: 20809215
9. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011; 332(6027):361-365. doi: 10.1126/science.1192152 PMID: 21493863
10. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005; 241(1):92-101. PMID: 15621996
11. Samson R. Can pharmacologic agents slow abdominal aortic aneurysm growth? Semin Vasc Surg. 2012; 25(1):25-28. doi: 10.1053/j.semvascsurg.2012.03.004 PMID: 22595478
12. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001; 34(4):606-610. PMID: 11668312
13. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol. 1999; 18(1):52-57. PMID: 10392481
14. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg. 2002; 35(1):72-79. PMID: 11802135
15. Karlsson L, Gnarpe J, Bergqvist D, Lindbäck J, Pärsson H. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms-a prospective randomized double-blind trial. J Vasc Surg. 2009; 50(1):23-29. doi: 10.1016/j.jvs.2008.12.048 PMID: 19563951
16. Kurosawa K, Matsumura JS, Yamanouchi D. Current status of medical treatment for abdominal aortic aneurysm. Circ J. 2013; 77(12):2860-2866. PMID: 24161907
17. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis. 1987; 65(1-2):13-21. PMID: 3649236
18. Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg. 1994; 2(4):484-8. PMID: 7953454
19. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995; 96(1):318-26. PMID: 7615801
20. López-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 1997; 150(3):993-1007. PMID: 9060837
21. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg. 2004; 40(2):334-338. PMID: 15297830
22. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6(12):815-823. doi: 10.1038/nnano.2011.166 PMID: 22020122
23. Miura Y, Takenaka T, Toh K, Wu S, Nishihara H, Kano MR, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano. 2013; 7:8583-8592. doi: 10.1021/nn402662d PMID: 24028526
24. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichloro(1, 2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release. 2005; 101(1-3):223-232. PMID: 15588907
25. Cabral H, Nishiyama N, Kataoka K. Optimization of (1, 2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release. 2007; 121(3):146-155. PMID: 17628162
26. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation. 1990; 82(3):973-981. PMID: 2144219
27. Anidjar S, Dobrin PB, Eichorst M, Graham GP, Chejfec G. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg. 1992; 16(2):139-147. PMID: 1386635
28. Nugent LJ, Jain RK. Two-compartment model for plasma pharmacokinetics in individual blood vessels. J Pharmacokinet Biopharm. 1984; 12(4):451-461. PMID: 6084709
29. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Distribution of sirolimus in rat tissue. Clin Biochem. 1997; 30(2):135-142. PMID: 9127695
30. Woo HN, Chung HK, Ju EJ, Jung J, Kang HW, Lee SW, et al. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int J Nanomedicine. 2012; 7:2197-2208. doi: 10.2147/IJN.S29480 PMID: 22619555
31. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003; 63(24):8977-8983. PMID: 14695216
32. Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, et al. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol. 2012; 181(4):1250-1270. doi: 10.1016/j.ajpath.2012.06.036 PMID: 22889846
33. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZRAD and rapamycin in rats. Drug Metab Dispos. 1999; 27(5):627-632. PMID: 10220493
34. Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly (ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J Control Release. 2006; 110(2):370-377. PMID: 16298448
35. Yáñez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ϵ-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008; 61(1):133-144. PMID: 17393166
36. Harada M, Bobe I, Saito H, Shibata N, Tanaka R, Hayashi T, et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci 2011; 102(1):192-9. doi: 10. 1111/j.1349-7006.2010.01745.x PMID: 21040218
37. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichloro(1, 2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 2005 3; 101(1-3):223-32. PMID: 15588907
38. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005; 93(6):678-87. PMID: 16222314
39. Thompson RW, Curci JA, Ennis TL, Mao D, Pagano MB, Pham CT. Pathophysiology of abdominal aortic aneurysms: insights from the elastase-induced model in mice with different genetic backgrounds. Ann N Y Acad Sci. 2006; 1085:59-73. PMID: 17182923
40. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004; 24(3):429-434. PMID: 14739119
41. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Heinecke J, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg. 2001; 34(4):730-738. PMID: 11668331
42. Newman KM, Ogata Y, Malon AM, Irizarry E, Gandhi RH, Nagase H, et al. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb. 1994; 14(8):1315-1320. PMID: 8049193
43. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol. 1995; 15(8):1139-1144. PMID: 7627707
44. McMillan WD, Patterson BK, Keen RR, Pearce WH. In situ localization and quantification of seventytwo- kilodalton type IV collagenase in aneurysmal, occlusive, and normal aorta. J Vasc Surg 1995; 22 (3):295-305. PMID: 7674473
45. Davis V, Persidskaia R, Baca-Regen L, Itoh Y, Nagase H, Persidsky Y, et al. Matrix metalloproteinase- 2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 1998; 18(10):1625-1633. PMID: 9763536
46. Keen RR, Nolan KD, Cipollone M, Scott E, Shively VP, Yao JS, et al. Interleukin-1 beta induces differential gene expression in aortic smooth muscle cells. J Vasc Surg. 1994; 20(5):774-784; discussion 784-786. PMID: 7966813
47. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg. 1995; 21(5):761-772. PMID: 7539511
48. Choke E, Cockerill GW, Dawson J, Wilson RW, Jones A, Loftus IM, et al. Increased angiogenesis at the site of abdominal aortic aneurysm rupture. Ann N Y Acad Sci. 2006; 1085:315-319. PMID: 17182949
49. Reeps C, Pelisek J, Seidl S, Schuster T, Zimmermann A, Kuehnl A, et al. Inflammatory infiltrates and neovessels are relevant sources of MMPs in abdominal aortic aneurysm wall. Pathobiology. 2009; 76 (5):243-252. doi: 10.1159/000228900 PMID: 19816084
50. Nooteboom A, Van Der Linden CJ, Hendriks T. Tumor necrosis factor-alpha and interleukin-1beta mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood. Crit Care Med. 2002; 30(9):2063-2068. PMID: 12352042
51. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-1380. PMID: 10751361
52. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007; 82(4):381-388. PMID: 17728765
53. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9(5):324-337. doi: 10.1038/nri2546 PMID: 19390566